![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Janssen’s Schizophrenia Injection Invega Trinza
FDA Approves Janssen’s Schizophrenia Injection Invega Trinza
![ApprovedGreen.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/ApprovedGreen.gif?t=1576044289&width=430)
May 26, 2015
Janssen Pharmaceuticals plans to make its long-acting atypical schizophrenia therapy Invega Trinza commercially available by mid-June, following FDA approval last week.
Invega Trinza (three-month paliperidone palmitate) is the first and only schizophrenia drug to be administered just four times a year, providing the longest dosing interval available, the company says. It was approved under a priority review which cuts the NDA review time from the standard 10 months to just six.
In a long-term Phase 3 maintenance trial, 93 percent of patients treated with the drug didn’t experience a significant return of schizophrenia symptoms.
Prior to starting Invega Trinza, patients must be adequately treated with Invega Sustenna (one-month paliperidone palmitate) for at least four months. Last November, the FDA approved two sNDAs for Invega Sustenna to treat patients with schizoaffective disorder. — Jonathon Shacat
Upcoming Events
-
21Oct